Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rochelle M Maher

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of the American Academy of Dermatology|September 25, 2002
Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infectionsAlan B Fleischer, Mark Ling, Lawrence Eichenfield, et al.
The Lancet. Infectious Diseases|August 2, 2016
The VITAL study: case control studies are hypothesis-generating - Authors' replyOliver A Cornely, Rochelle M Maher, Francisco M Marty, et al.
Mycoses|April 4, 2018
Isavuconazole for treatment of rare invasive fungal diseasesOliver A Cornely, Kathleen M Mullane, Luis Ostrosky-Zeichner, et al.
Mycoses|April 4, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal speciesFrancisco M Marty, Oliver A Cornely, Kathleen M Mullane, et al.
Lancet (London, England)|December 20, 2015
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialJohan A Maertens, Issam I Raad, Kieren A Marr, et al.
The Lancet. Infectious Diseases|March 13, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisFrancisco M Marty, Luis Ostrosky-Zeichner, Oliver A Cornely, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of the American Academy of Dermatology|September 25, 2002
Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infectionsAlan B Fleischer, Mark Ling, Lawrence Eichenfield, et al.
The Lancet. Infectious Diseases|August 2, 2016
The VITAL study: case control studies are hypothesis-generating - Authors' replyOliver A Cornely, Rochelle M Maher, Francisco M Marty, et al.
Mycoses|April 4, 2018
Isavuconazole for treatment of rare invasive fungal diseasesOliver A Cornely, Kathleen M Mullane, Luis Ostrosky-Zeichner, et al.
Mycoses|April 4, 2018
Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal speciesFrancisco M Marty, Oliver A Cornely, Kathleen M Mullane, et al.
Lancet (London, England)|December 20, 2015
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trialJohan A Maertens, Issam I Raad, Kieren A Marr, et al.
The Lancet. Infectious Diseases|March 13, 2016
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysisFrancisco M Marty, Luis Ostrosky-Zeichner, Oliver A Cornely, et al.
Pageof 1